Aerie Pharmaceuticals Inc. (NASDAQ:AERI)’s share price traded up 2.4% on Tuesday . The stock traded as high as $19.58 and last traded at $19.45, with a volume of 119,952 shares changing hands. The stock had previously closed at $18.99.

Several research firms recently commented on AERI. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $20.00 price objective on the stock in a research report on Monday, July 4th. Cantor Fitzgerald began coverage on Aerie Pharmaceuticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $44.00 price objective on the stock. Brean Capital reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, May 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $45.00 price objective on shares of Aerie Pharmaceuticals in a research report on Tuesday, August 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $42.50.

The stock’s market cap is $539.99 million. The stock has a 50-day moving average of $18.27 and a 200 day moving average of $16.33.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. Equities analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.74) EPS for the current fiscal year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of the stock in a transaction on Friday, July 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.